Bone selective effect of an estradiol conjugate with a novel tetracycline-derived bone-targeting agent
Authors:
- William M. PierceWPWilliam M. Pierce
- 1 February 2009
- journal article
- research article
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 19 (3) , 680-683
Abstract
No abstract availableKeywords
This publication has 16 references indexed in Scilit:
- Chemotherapeutic bone-targeted bisphosphonate prodrugs with hydrolytic mode of activationBioorganic & Medicinal Chemistry Letters, 2008
- Bone-Specific Drug Delivery SystemsClinical Pharmacokinetics, 2003
- Bone as an Effect CompartmentClinical Pharmacokinetics, 2003
- Bisphosphonates as a Foundation of Drug Delivery to BoneCurrent Pharmaceutical Design, 2002
- Novel Drug Delivery System to Bone Using Acidic Oligopeptide: Pharmacokinetic Characteristics and Pharmacological PotentialJournal of Drug Targeting, 2001
- Prostaglandin E2-bisphosphonate conjugates: potential agents for treatment of osteoporosisBioorganic & Medicinal Chemistry, 1999
- Osteotropic Drug Delivery System (ODDS) Based on Bisphosphonic Prodrug. IV Effects of Osteotropic Estradiol on Bone Mineral Density and Uterine Weight in Ovariectomized RatsJournal of Drug Targeting, 1998
- Osteotropic Drug Delivery System (ODDS) Based on Bisphosphonic Prodrug. V. Biological Disposition and Targeting Characteristics of Osteotropic Estradiol.Biological and Pharmaceutical Bulletin, 1997
- Osteotropic Drug Delivery System (ODDS) Based on Bisphosphonic Prodrug. I: Synthesis and in Vivo Characterization of Osteotropic CarboxyfluoresceinJournal of Drug Targeting, 1995
- Synthesis of β-estradiol-3-benzoate-17-(succinyl-12A-tetracycline): A potential bone-seeking estrogenBioorganic & Medicinal Chemistry Letters, 1994